Latest News
American Regent to Acquire Generic Drug Maker HBT Labs
Thursday 18 August 2022

US-based injectable pharmaceuticals manufacturer American Regent, Inc., with manufacturing sites in New York and Ohio, has acquired California-based HBT Labs, Inc, the company said.

HBT Labs has a pipeline of generic and 505(b) (2) pharmaceutical products that target various treatment indications including cancer and Central Nervous System disorders.

With the acquisition, American Regent will support the existing commercialization of HBT's authorized generic that is managed through a partner, in addition to supporting the launch of HBT's FDA approved 505(b) (2) New Drug Application providing for the use of Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound), lyophilized powder for reconstitution, 100 mg/vial.

HBT Labs will function as a wholly owned subsidiary of American Regent, Inc., and will continue research and development and commercial operations in Brea, California.

American Regent financed the transaction with existing cash on hand.

American Regent, Inc., a subsidiary of Japan's Daiichi Sankyo Group, is an injectable manufacturer.

For over 50 years, American Regent has been developing, manufacturing, and supplying generic and branded injectables for healthcare providers.

This expansion will nearly double its capacity, the company said.
Date Published: 18/08/2022